Gene therapy makers slide on reports that FDA official Peter Marks resigns

Solid Biosciences

31/03/2025 17:28

Updates

** Shares of gene therapy makers and developers slide after WSJ and other media outlets report that Peter Marks, a top official at the US FDA, has been pushed out of the agency

** Marks was the head of FDA's Center for Biologics Evaluation and Research (CBER) and introduced several programs to accelerate the development of gene and cell therapies during his tenure

** Taysha Gene Therapies TSHA.O down 30.3%, Solid Biosciences SLDB.O down 15.3%

** US-listed shares of CRISPR Therapeutics CRSP.O down 8.7%, Sarepta Therapeutics SRPT.O down 9.2%

** "Gene and cell therapies likely under increased pressure, given CBER and Marks' intimate relationship with many of these companies and programs," says BMO Capital Markets analyst Evan Seigerman

** Marks was given the choice by a Health and Human Services official to resign or be fired, according to WSJ, which also reported that his resignation is effective April 5

(Reporting by Manas Mishra and Christy Santhosh)

((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))